Literature DB >> 19843085

Serum cytokines and growth factor levels in Japanese patients with psoriasis.

H Takahashi1, H Tsuji, Y Hashimoto, A Ishida-Yamamoto, H Iizuka.   

Abstract

BACKGROUND: Although the precise pathomechanism of psoriasis is still unknown, various cytokines and growth factors derived from T cells, dendritic cells or keratinocytes, are critically involved in this disease. There have been several studies determining the serum levels of cytokines in patients with psoriasis, but with conflicting results. The levels of various cytokines and growth factors were measured in the sera of patients with psoriasis and compared with those of healthy controls. The correlation with disease severity was also determined.
METHODS: Sera were collected from 122 patients with psoriasis and 78 healthy controls for ELISA analysis to evaluate the levels of cytokines and growth factors. The severity of psoriasis was determined by the Psoriasis Area and Severity Index (PASI).
RESULTS: Serum levels of tumour necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-2, IL-6, IL-7, IL-8, IL-12, IL-17, IL-18 and vascular endothelial growth factor (VEGF) were significantly increased in patients with psoriasis compared with those of healthy controls. The serum levels of IL-2, soluble intercellular adhesion molecule-1, epidermal growth factor, hepatocyte growth factor and amphiregulin were not significantly different from those of healthy controls. Increased serum levels of TNF-alpha, IFN-gamma, IL-12, IL-17, IL-18 and VEGF correlated with PASI. Furthermore, these cytokine levels were decreased after psoriasis treatment. In contrast, serum levels of IL-10 were decreased in psoriasis and negatively correlated with PASI. DISCUSSION: Serum levels of TNF-alpha, IFN-gamma, IL2, IL-6, IL-7, IL-8, IL-12, IL-17, IL-18 and VEGF were positively correlated and that of IL-10 was negatively correlated with PASI in Japanese patients with psoriasis. These parameters might be useful for determining the disease activity of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843085     DOI: 10.1111/j.1365-2230.2009.03704.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  55 in total

1.  Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.

Authors:  A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger
Journal:  Br J Dermatol       Date:  2015-11-11       Impact factor: 9.302

2.  Expression of tumor necrosis factor alpha-induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris.

Authors:  Xuebing Jiang; Hongqing Tian; Yuchen Fan; Jie Chen; Yonghong Song; Shurong Wang; Faliang Zhu; Chun Guo; Lining Zhang; Yongyu Shi
Journal:  Clin Vaccine Immunol       Date:  2012-10-10

3.  Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes.

Authors:  Mei-ling Xuan; Chuan-jian Lu; Ling Han; Yu Xiang
Journal:  Chin J Integr Med       Date:  2014-12-19       Impact factor: 1.978

4.  IL-17A potentiates TNFα-induced secretion from human endothelial cells and alters barrier functions controlling neutrophils rights of passage.

Authors:  Markus H Bosteen; Katerina Tritsaris; Anker J Hansen; Steen Dissing
Journal:  Pflugers Arch       Date:  2013-09-27       Impact factor: 3.657

5.  Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.

Authors:  Camila Cataldi; Naiara Lourenço Mari; Marcell Alysson Batisti Lozovoy; Ligia Márcia Mário Martins; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi; Andréa Name Colado Simão
Journal:  Inflamm Res       Date:  2019-05-06       Impact factor: 4.575

Review 6.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

7.  Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation.

Authors:  Koichi Yanaba; Masahiro Kamata; Nobuko Ishiura; Sayaka Shibata; Yoshihide Asano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  J Leukoc Biol       Date:  2013-04-29       Impact factor: 4.962

Review 8.  Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

Authors:  Jillian Frieder; Dario Kivelevitch; Alan Menter
Journal:  Ther Adv Chronic Dis       Date:  2017-11-16       Impact factor: 5.091

9.  Is microRNA 1910-3p (miR-1910-3p) a really distinctive marker for psoriasis?

Authors:  Melek Karabacak; İjlal Erturan; Kuyaş Hekimler Öztürk; Havva Hilal Ayvaz; Selma Korkmaz; Mehmet Yıldırım; Hikmet Orhan
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

10.  Assessment of Selected Matrix Metalloproteinases (MMPs) and Correlation with Cytokines in Psoriatic Patients.

Authors:  Anna Michalak-Stoma; Joanna Bartosińska; Dorota Raczkiewicz; Małgorzata Kowal; Dorota Krasowska; Grażyna Chodorowska
Journal:  Mediators Inflamm       Date:  2021-06-29       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.